Altimmune (ALT) Receivables - Net (2010 - 2026)
Altimmune (ALT) posted quarterly Receivables - Net of $1.7 million for Q1 2026, up 228.4% year-over-year from $507000.0 in Q1 2025, and up 36.59% quarter-over-quarter from $1.2 million in Q4 2025.
Powered by 
Analysis
Altimmune (ALT) Receivables - Net (2010 - 2026) Analysis & Trends
Altimmune (ALT) has reported Receivables - Net for 17 consecutive years, with $1.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables - Net rose 228.4% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $1.7 million (up 228.4% YoY), while the FY2025 annual figure was $1.2 million, up 124.08% from the prior year.
- Receivables - Net rose to $1.7 million in Q1 2026 per ALT's latest filing, from $1.2 million in the prior quarter.
- Across five years, Receivables - Net topped out at $1.7 million in Q1 2026 and bottomed at $136000.0 in Q2 2023.
- Historically, Receivables - Net has averaged $578176.5 across 5 years, with a median of $428000.0 in 2024.
- Annual changes were most pronounced in 2022 — Receivables - Net slumped 95.98% — and 2023, when it soared 542.2%.
- Altimmune's Receivables - Net stood at $173000.0 in 2022, then jumped by 542.2% to $1.1 million in 2023, then sank by 51.04% to $544000.0 in 2024, then jumped by 124.08% to $1.2 million in 2025, then jumped by 36.59% to $1.7 million in 2026.
- Business Quant data shows ALT's Receivables - Net at $1.7 million in Q1 2026, $1.2 million in Q4 2025, and $845000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Altimmune | 636.07 Mn | 636.07 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.34 Mn |
| Mar 31, 2026 | 1.67 Mn |
| Dec 31, 2025 | 1.22 Mn |
| Sep 30, 2025 | 845,000.00 |
| Jun 30, 2025 | 321,000.00 |
| Mar 31, 2025 | 507,000.00 |
| Dec 31, 2024 | 544,000.00 |
| Sep 30, 2024 | 428,000.00 |
| Jun 30, 2024 | 424,000.00 |
| Mar 31, 2024 | 307,000.00 |
| Dec 31, 2023 | 1.11 Mn |
| Sep 30, 2023 | 876,000.00 |
| Jun 30, 2023 | 136,000.00 |
| Mar 31, 2023 | 252,000.00 |
| Dec 31, 2022 | 173,000.00 |
| Sep 30, 2022 | 633,000.00 |
| Jun 30, 2022 | 195,000.00 |
| Mar 31, 2022 | 193,000.00 |
| Dec 31, 2021 | 429,000.00 |
| Sep 30, 2021 | 1.57 Mn |